← Back to Search

Iodine-124 Imaging for Thyroid Cancer

Phase 1
Recruiting
Led By Ravinder Grewal, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adults with thyroid carcinoma confirmed by pathology
Adult thyroid carcinoma patients who have undergone total thyroidectomy
Must not have
Age less than 18 years
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new imaging method to see how well cancer cells absorb a special type of iodine. It aims to help doctors decide if patients should continue with their current treatment or switch to a different one based on the scan results. The special iodine has been used to improve accuracy in cancer treatment.

Who is the study for?
This trial is for adults with confirmed thyroid carcinoma who've had their thyroid removed and either have metastatic disease or are suspected to. They should be planning on radioiodine therapy if persistent cancer that absorbs iodine is found, and must have measurable disease documented in the last six months.
What is being tested?
The study tests a new PET scan using radioactive iodine-124 to see how much iodine the cancer takes up. This helps decide if standard radioiodine therapy will work or if another treatment is better. The test could lead to continuing usual treatment or switching strategies based on uptake levels.
What are the potential side effects?
Since this trial focuses on diagnostic imaging rather than a therapeutic intervention, side effects may include discomfort from the PET/CT procedure, potential allergic reactions to contrast agents used during imaging, and exposure to radiation.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My thyroid cancer diagnosis is confirmed by a pathology report.
Select...
I had my entire thyroid removed due to cancer.
Select...
I am considering 131I therapy for my thyroid cancer metastases.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am under 18 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
number of individual lesions response

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Lesion Dosimetry With Iodine-124Experimental Treatment2 Interventions
Patients will be administered 124I and undergo serial PET imaging consisting of up to 4 individual PET/CT scans. In order to perform a dual exponential fit, 4 scans are needed to obtain the necessary amount of data points required. Lesion dosimetry shall be performed based on the 124I PET scan data through tumor uptake and clearance pharmacokinetics. 10 patients, who sign consent for the sub-study, will be administered an additional tracer diagnostic activity of 124I (4 to 7 mCi). These patients will then undergo additional (up to a maximum of 4) PET scanning during radioiodine therapy at time points matched, if possible, to the days of the pre-therapy 124I dosimetry study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PET/CT Scan
2013
Completed Phase 2
~1370

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for thyroid cancer include radioactive iodine therapy, surgery, and external beam radiotherapy (EBRT). Radioactive iodine therapy works by using radioactive iodine-131, which is selectively taken up by thyroid cells, including cancerous ones, to destroy them from within. This is particularly effective for differentiated thyroid cancers that absorb iodine. Surgery involves the removal of the thyroid gland (thyroidectomy) and is often the first line of treatment to physically eliminate the tumor. EBRT uses high-energy radiation to target and kill cancer cells, and is typically used when the cancer is not iodine-avid or has spread to surrounding tissues. These treatments are crucial as they offer targeted approaches to eliminate cancer cells, reduce recurrence, and improve survival rates for thyroid cancer patients.
Renal and Red Marrow Dosimetry in Peptide Receptor Radionuclide Therapy: 20 Years of History and Ahead.Clinical translation of theranostic radiopharmaceuticals: Current regulatory status and recent examples.Effects of recombinant human thyroid-stimulating hormone superagonists on thyroidal uptake of 18F-fluorodeoxyglucose and radioiodide.

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,977 Previous Clinical Trials
599,667 Total Patients Enrolled
Ravinder Grewal, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
4 Previous Clinical Trials
35 Total Patients Enrolled

Media Library

PET/CT Scan Clinical Trial Eligibility Overview. Trial Name: NCT03647358 — Phase 1
Thyroid Cancer Research Study Groups: Lesion Dosimetry With Iodine-124
Thyroid Cancer Clinical Trial 2023: PET/CT Scan Highlights & Side Effects. Trial Name: NCT03647358 — Phase 1
PET/CT Scan 2023 Treatment Timeline for Medical Study. Trial Name: NCT03647358 — Phase 1
~12 spots leftby Aug 2026